GSK3B and neurodegenerative disease: Activation of GSK3β has been described in a variety of neurodegenerative diseases, also using in vitro and in vivo ALS models and several GSK3β inhibitors have been tested in clinical trials related to Alzheimer’s disease and ALS [108].